GPC-100-001 | MM Clinical Trial

What is the GPC-100-001 study?

The GPC-100-001 clinical research study is for patients who have Multiple Myeloma. The study will explore whether a combination of 2 study drugs is safe and effective for people with Multiple Myeloma whose stem cells are being mobilized for Autologous Stem Cell Transplant (ASCT).

Who can join the GPC-100-001 study?

Study participants may be able to join the study if they meet the following requirements:

18 years of age or older
Patients with confirmed diagnosis of Multiple Myeloma
Individuals who have never had a stem cell transplant

Other study requirements will apply.

Do I Qualify?

What will happen during the study?

Participation in the GPC-100-001 study lasts about 2-5 months total. Study participants can expect the following:

Review & sign the Informed Consent Form.
Screening: Visit the study clinic twice for assessments to confirm if you qualify for the study.
Study Treatment period: Visit the study clinic up to 12 times. During your visits, you will receive the study drugs and then your stem cells will be collected. You may also receive another medication that is approved for the mobilization of stem cells. After completing all apheresis sessions, you and your doctor will discuss whether you will receive ASCT.
Follow-up period (1 month after your last apheresis session): Visit the study clinic again to determine how your body responded to apheresis. If you also receive ASCT, you may have 2 more visits.

Participation in a clinical study is voluntary. You can ask any questions and may leave the study at any time, for any reason.